Therapy Areas: Autoimmune
Hansa Medical's board resolves on issue and repurchase of class C shares
7 September 2018 -

Hansa Medical AB (STO:HMED) announced on Thursday that under the authorisation by the annual general meeting held on 29 May 2018, the company's board of directors of has resolved to issue and immediately thereafter repurchase 391,503 class C shares.

These shares are issued and repurchased in accordance with the incentive programme LTIP 2018, which was adopted by the annual general meeting held on 29 May 2018.

Reportedly, Carnegie Investment Bank AB will subscribe for the entire issue of new class C shares at a subscription price of SEK1 per share, corresponding to the quota value of the shares. The entire issue of class C shares will thereafter, in accordance with the board of directors' resolution, be repurchased by Hansa Medical for the same price.

These class C shares will be converted into ordinary shares prior to delivery to qualifying participants of LTIP 2018.

According to the company, the purpose of the repurchase is to ensure delivery of shares and to secure possible social charges arising as a result of LTIP 2018. These class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

Hansa Medical has previously issued 330,261 class C shares.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.

(EUR1.00=SEK10.59)

Login
Username:

Password: